Mylan misses a beat on numbers

Drugmaker Mylan missed revenue and profit expectations in the second quarter and the company said it has a more conservative outlook because of “ongoing challenges and the uncertain US regulatory environment”.

The company said profits rose 76 per cent to $297 million (£228.2m), or 55 cents per share, in the period.